BioStock: Sensidose ready for expansion and IPO

Sensidose is a pharmaceutical company that sells a proprietary, non-invasive and personalized dosing system for Parkinson’s patients, who are towards the later phases of the disease. The company’s medicine and dosing system is currently marketed in Sweden, Norway and Denmark, and Sensidose aims to expand to more geographic markets. Furthermore Sensidose is developing its treatment system with a new dosing device aimed towards patients who are in an earlier stage of the disease. As Sensidose is preparing for an IPO in 2022, BioStock contacted CEO Jack Spira to find out more about the plans for the year and the possibilities of the company’s treatment.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/sensidose-ready-for-expansion-and-ipo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se